A binational cohort study of intestinal colonization with extended-spectrum β-lactamase-producing Proteus mirabilis in patients admitted to rehabilitation centres

Clinical Microbiology and Infection

Volumn 19, Issue 2, 2013, Pages

  Adler, A ^a   Baraniak, A ^b   Izdebski, R ^b   Fiett, J ^b   Gniadkowski, M ^b   Hryniewicz, W ^b   Salvia, A ^c   Rossini, A ^c   Goossens, H ^d   Malhotra, S ^d   Lerman, Y ^a   Elenbogen, M ^a   Carmeli, Y ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b NATIONAL MEDICINES INSTITUTE   (Poland)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Clones; Colonization; Extended spectrum lactamase; Proteus mirabilis; Rehabilitation centres

Indexed keywords

ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BRAIN INJURY; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DECUBITUS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GENE IDENTIFICATION; HUMAN; ISRAEL; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEUS MIRABILIS; PULSED FIELD GEL ELECTROPHORESIS; REHABILITATION CENTER; REHABILITATION PATIENT; RISK FACTOR;

PROTEUS MIRABILIS;

EID: 84873525170     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12072     Document Type: Article

References (46)

1. Cohen-Nahum K, Saidel-Odes L, Riesenberg K, Schlaeffer F, Borer A. Urinary tract infections caused by multi-drug resistant proteus mirabilis: risk factors and clinical outcomes. Infection 2010; 38: 41-46.
2. Endimiani A, Luzzaro F, Brigante G et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2005; 49: 2598-2605.
3. O'Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev 2000; 13: 534-546.
4. Chow AW, Taylor PR, Yoshikawa TT, Guze LB. A nosocomial outbreak of infections due to multiply resistant Proteus mirabilis: role of intestinal colonization as a major reservoir. J Infect Dis 1979; 139: 621-627.
5. Nagano N, Shibata N, Saitou Y, Nagano Y, Arakawa Y. Nosocomial outbreak of infections by Proteus mirabilis that produces extended-spectrum ctx-m-2 type beta-lactamase. J Clin Microbiol 2003; 41: 5530-5536.
6. Williams EW, Hawkey PM, Penner JL, Senior BW, Barton LJ. Serious nosocomial infection caused by Morganella morganii and Proteus mirabilis in a cardiac surgery unit. J Clin Microbiol 1983; 18: 5-9.
7. Biendo M, Thomas D, Laurans G et al. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital. Clin Microbiol Infect 2005; 11: 395-401.
8. de Champs C, Monne C, Bonnet R et al. New tem variant (tem-92) produced by Proteus mirabilis and Providencia stuartii isolates. Antimicrob Agents Chemother 2001; 45: 1278-1280.
9. D'Andrea MM, Literacka E, Zioga a et al. Evolution and spread of a multidrug-resistant Proteus mirabilis clone with chromosomal ampc-type cephalosporinases in Europe. Antimicrob Agents Chemother 2011; 55: 2735-2742.
10. Luzzaro F, Brigante G, D'Andrea MM et al. Spread of multidrug-resistant Proteus mirabilis isolates producing an ampc-type beta-lactamase: epidemiology and clinical management. Int J Antimicrob Agents 2009; 33: 328-333.
11. Kanayama A, Iyoda T, Matsuzaki K et al. Rapidly spreading ctx-m-type beta-lactamase-producing Proteus mirabilis in Japan. Int J Antimicrob Agents 2010; 36: 340-342.
12. Navon-Venezia S, Chmelnitsky I, Leavitt A, Carmeli Y. Dissemination of the ctx-m-25 family beta-lactamases among Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and identification of the novel enzyme ctx-m-41 in Proteus mirabilis in Israel. J Antimicrob Chemother 2008; 62: 289-295.
13. Empel J, Baraniak A, Literacka E et al. Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in enterobacteriaceae isolates from polish hospitals. Antimicrob Agents Chemother 2008; 52: 2449-2454.
14. Drieux L, Brossier F, Sougakoff W, Jarlier V. Phenotypic detection of extended-spectrum beta-lactamase production in enterobacteriaceae: review and bench guide. Clin Microbiol Infect 2008; 14 (suppl 1): 90-103.
15. Struelens MJ, Rost F, Deplano A et al. Pseudomonas aeruginosa and enterobacteriaceae bacteremia after biliary endoscopy: an outbreak investigation using DNA macrorestriction analysis. Am J Med 1993; 95: 489-498.
16. Literacka E, Empel J, Baraniak A, Sadowy E, Hryniewicz W, Gniadkowski M. Four variants of the Citrobacter freundii ampc-type cephalosporinases, including novel enzymes cmy-14 and cmy-15, in a Proteus mirabilis clone widespread in Poland. Antimicrob Agents Chemother 2004; 48: 4136-4143.
17. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-2239.
18. Bauernfeind A, Grimm H, Schweighart S. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection 1990; 18: 294-298.
19. Woodford N, Fagan EJ, Ellington MJ. Multiplex pcr for rapid detection of genes encoding ctx-m extended-spectrum (beta)-lactamases. J Antimicrob Chemother 2006; 57: 154-155.
20. Mabilat C, Goussard S, Sougakoff W, Spencer RC, Courvalin P. Direct sequencing of the amplified structural gene and promoter for the extended-broad-spectrum β-lactamase tem-9 (rhh-1) of Klebsiella pneumoniae. Plasmid 1990; 23: 27-34.
21. Samuelsen, Naseer U, Tofteland S et al. Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. J Antimicrob Chemother 2009; 63: 654-658.
22. Baraniak A, Fiett J, Sulikowska A, Hryniewicz W, Gniadkowski M. Countrywide spread of CTX-M-3 extended-spectrum β-lactamase (ESBL)-producing microorganisms of the family Enterobacteriaceae in Poland. Antimicrob Agents Chemother 2002; 46: 151-159.
23. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods 2005; 63: 219-228.
24. Perilli M, Segatore B, de Massis MR et al. Tem-72, a new extended-spectrum beta-lactamase detected in Proteus mirabilis and Morganella morganii in Italy. Antimicrob Agents Chemother 2000; 44: 2537-2539.
25. Sutcliffe JG. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pbr322. Proc Natl Acad Sci USA 1978; 75: 3737-3741.
26. Leflon-Guibout V, Heym B, Nicolas-Chanoine MH. Updated sequence information and proposed nomenclature for blatem genes and their promoters. Antimicrob Agents Chemother 2000; 44: 3232-3234.
27. Karim A, Poirel L, Nagarajan S, Nordmann P. Plasmid-mediated extended-spectrum beta-lactamase (ctx-m-3 like) from India and gene association with insertion sequence isecp1. FEMS Microbiol Lett 2001; 201: 237-241.
28. Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas JM. Sequences of beta-lactamase genes encoding ctx-m-1 (men-1) and ctx-m-2 and relationship of their amino acid sequences with those of other beta-lactamases. Antimicrob Agents Chemother 1996; 40: 509-513.
29. Munday CJ, Boyd DA, Brenwald N et al. Molecular and kinetic comparison of the novel extended-spectrum beta-lactamases ctx-m-25 and ctx-m-26. Antimicrob Agents Chemother 2004; 48: 4829-4834.
30. Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber MJ, Navon-Venezia S. Ctx-m-2 and a new ctx-m-39 enzyme are the major extended-spectrum beta-lactamases in multiple Escherichia coli clones isolated in Tel Aviv, Israel. Antimicrob Agents Chemother 2005; 49: 4745-4750.
31. Vervoort J, Gazin M, Lammens C et al. Characterization of two novel ctx-m-25 group extendedspectrum β-lactamases, ctx-m-94 and -100, recovered from patients at a tertiary care hospital in Israel. NVvM 2011. Arnhem, The Netherlands, 2011.
32. Luzzaro F, Mezzatesta M, Mugnaioli C et al. Trends in production of extended-spectrum beta-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol 2006; 44: 1659-1664.
33. Perilli M, Segatore B, Mugnaioli C et al. Persistence of tem-52/tem-92 and shv-12 extended-spectrum beta-lactamases in clinical isolates of enterobacteriaceae in Italy. Microb Drug Resist 2011; 17: 521-524.
34. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-686.
35. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001; 14: 244-269.
36. Migliavacca R, Migliavacca A, Nucleo E et al. Molecular epidemiology of esbetal producing P. mirabilis strains from a long-term care and rehabilitation facility in Italy. New Microbiol 2007; 30: 362-366.
37. Cantón R, Novais A, Valverde A et al. Prevalence and spread of extended-spectrum beta-lactamase-producing enterobacteriaceae in Europe. Clin Microbiol Infect 2008; 14 (suppl 1): 144-153.
38. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of ctx-m-type extended-spectrum beta-lactamases. Clin Microbiol Infect 2008; 14 (suppl 1): 33-41.
39. Livermore DM, Canton R, Gniadkowski M et al. Ctx-m: changing the face of esbls in Europe. J Antimicrob Chemother 2007; 59: 165-174.
40. Izdebski R, Braniak A, Herda M et al. Clonal structure, esbls and acquired ampcs of Escherichia coli populations colonising patients in rehabilitation centres in four countries. ECCMID 2012. London, UK, 2012.
41. Schlesinger J, Navon-Venezia S, Chmelnitsky I et al. Extended-spectrum beta-lactamases among enterobacter isolates obtained in Tel Aviv, Israel. Antimicrob Agents Chemother 2005; 49: 1150-1156.
42. Gniadkowski M, Schneider I, Jungwirth R, Hryniewicz W, Bauernfeind A. Ceftazidime-resistant enterobacteriaceae isolates from three polish hospitals: identification of three novel tem- and shv-5-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42: 514-520.
43. Barlow M, Fatollahi J, Salverda M. Evidence for recombination among the alleles encoding tem and shv beta-lactamases. J Antimicrob Chemother 2009; 63: 256-259.
44. Carattoli A. Resistance plasmid families in enterobacteriaceae. Antimicrob Agents Chemother 2009; 53: 2227-2238.
45. Harada S, Ishii Y, Saga T, Kouyama Y, Tateda K, Yamaguchi K. Chromosomal integration and location on inct plasmids of the blactx-m-2 gene in Proteus mirabilis clinical isolates. Antimicrob Agents Chemother 2012; 56: 1093-1096.
46. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli o25b-st131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66: 1-14.